JP7369039B2 - 標的化タンパク質分解 - Google Patents

標的化タンパク質分解 Download PDF

Info

Publication number
JP7369039B2
JP7369039B2 JP2019572373A JP2019572373A JP7369039B2 JP 7369039 B2 JP7369039 B2 JP 7369039B2 JP 2019572373 A JP2019572373 A JP 2019572373A JP 2019572373 A JP2019572373 A JP 2019572373A JP 7369039 B2 JP7369039 B2 JP 7369039B2
Authority
JP
Japan
Prior art keywords
car
cells
domain
cell
ubiquitin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019572373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529970A (ja
JP2020529970A5 (cg-RX-API-DMAC10.html
Inventor
リー ブライショー，ルイス
メンティース ハン，マイケル
ヘリング，クリストファー
フレイテス，カルロス マルティネス
アレクサンダー ケイサー，マルクス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2020529970A publication Critical patent/JP2020529970A/ja
Publication of JP2020529970A5 publication Critical patent/JP2020529970A5/ja
Application granted granted Critical
Publication of JP7369039B2 publication Critical patent/JP7369039B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019572373A 2017-07-03 2018-07-02 標的化タンパク質分解 Active JP7369039B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1710620.4 2017-07-03
GBGB1710620.4A GB201710620D0 (en) 2017-07-03 2017-07-03 Targeted protein degradation
PCT/EP2018/067741 WO2019007869A1 (en) 2017-07-03 2018-07-02 TARGETED DEGRADATION OF PROTEINS

Publications (3)

Publication Number Publication Date
JP2020529970A JP2020529970A (ja) 2020-10-15
JP2020529970A5 JP2020529970A5 (cg-RX-API-DMAC10.html) 2021-07-26
JP7369039B2 true JP7369039B2 (ja) 2023-10-25

Family

ID=59592357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019572373A Active JP7369039B2 (ja) 2017-07-03 2018-07-02 標的化タンパク質分解

Country Status (8)

Country Link
US (2) US10683360B2 (cg-RX-API-DMAC10.html)
EP (1) EP3649149A1 (cg-RX-API-DMAC10.html)
JP (1) JP7369039B2 (cg-RX-API-DMAC10.html)
CN (1) CN110997710A (cg-RX-API-DMAC10.html)
BR (1) BR112019028024A2 (cg-RX-API-DMAC10.html)
CA (1) CA3068365A1 (cg-RX-API-DMAC10.html)
GB (2) GB201710620D0 (cg-RX-API-DMAC10.html)
WO (1) WO2019007869A1 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
CA3075716A1 (en) * 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Anti-BCMA Antibody Drug Conjugate Combination Treatment for Cancer
SG11202003415XA (en) * 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
WO2019089592A1 (en) * 2017-10-31 2019-05-09 The General Hospital Corporation Molecular switch-mediated control of engineered cells
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
EP3908592A1 (en) * 2019-01-07 2021-11-17 University of Washington De novo design of protein switches for tunable control of protein degradation
US12583896B2 (en) 2019-01-07 2026-03-24 The Regents Of The University Of California Caged-degron-based molecular feedback circuits and methods of using the same
CN111825769B (zh) * 2019-04-16 2022-03-25 上海科技大学 一种泛素化缺失的嵌合抗原受体及其用途
WO2020219742A1 (en) * 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
NZ788436A (en) * 2019-11-27 2025-08-29 Onegene Biotechnology Inc Multifunctional multispecific multimeric biomolecule polymer having prolonged in-vivo duration
KR102626782B1 (ko) * 2020-02-14 2024-01-19 주식회사 셀젠텍 B세포 성숙화 항원을 표적으로 하는 키메라 항원 수용체 및 이의 용도
CN114057890A (zh) * 2020-07-31 2022-02-18 南京北恒生物科技有限公司 新型共刺激结构域及其用途
US20230355764A1 (en) 2020-09-13 2023-11-09 Shandong Boan Biotechnology Co., Ltd. Downregulation of membrane-bound proteins by receptor tac technology
CN112266404A (zh) * 2020-10-28 2021-01-26 北京大学深圳研究生院 选择性修饰靶标蛋白的基团转移方法及其应用
CN112940096A (zh) * 2021-01-29 2021-06-11 西安交通大学 一种膀胱癌血清多肽标志物及其应用
CA3207206A1 (en) * 2021-02-01 2022-08-04 Lingfeng LIU Targeted protein degradation system and use thereof
CN112980882A (zh) * 2021-03-15 2021-06-18 上海科技大学 Crbn基因在构建GSPT1敏感模型中的用途
JP2024528988A (ja) * 2021-08-06 2024-08-01 セルジーン コーポレーション 改変タンパク質の選択的分解のための組成物および方法
NL2031325B1 (en) 2022-03-18 2023-09-29 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Novel zinc finger degron sequences
KR20250120279A (ko) 2022-12-01 2025-08-08 에테하 취리히 변형된 아미노산 데그론(maad)을 식별하기 위한 방법
NL2037809B1 (en) 2024-05-29 2025-12-12 Cell Control Biotherapeutics Inc Loop reinforcement expression system for improved cell therapy products
CN119699269B (zh) * 2024-07-10 2025-10-17 太原市中心医院 基于sbsn 600位赖氨酸发生二羟基异丁酰化修饰的用于银屑病研究的小鼠模型构建方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2457095A1 (en) * 2001-08-17 2003-02-27 Toolgen, Inc. Zinc finger domain libraries
WO2012149299A2 (en) * 2011-04-29 2012-11-01 Celgene Corporaiton Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
RU2582259C2 (ru) * 2012-02-24 2016-04-20 Алтеоген Инк. Модифицированные антитела, с которыми связан мотив, включающий остаток цистеина, конъюгаты этих модифицированных антител с лекарственными веществами и способ их получения
CN103265635A (zh) * 2013-04-28 2013-08-28 中山大学附属第一医院 一种通用的靶向蛋白嵌合型分子化合物的构建方法
EP4649963A3 (en) * 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
CA2964161A1 (en) * 2014-10-10 2016-04-14 Dana-Farber Cancer Institute, Inc. Methods for discovering therapeutics that alter the stability of target proteins
US11168345B2 (en) * 2015-09-11 2021-11-09 The Broad Institute, Inc. Methods of identifying a polypeptide target for degradation by a modulator of CRBN
US10830762B2 (en) * 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
CN109983027A (zh) * 2016-10-20 2019-07-05 细胞基因公司 基于cereblon的可异二聚化嵌合抗原受体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry，2017年04月20日，Vol. 61，p. 535-542，doi:10.1021/acs.jmedchem.6b01921
NATURE，2016年04月07日，Vol. 532，p. 127-130, Supplementary Information，doi:10.1038/nature16979
NATURE，2016年06月22日，Vol. 535，p. 252-257, Supplementary Information，doi:10.1038/nature18611

Also Published As

Publication number Publication date
US11427643B2 (en) 2022-08-30
US10683360B2 (en) 2020-06-16
GB2568987A (en) 2019-06-05
BR112019028024A2 (pt) 2020-07-07
JP2020529970A (ja) 2020-10-15
US20190002578A1 (en) 2019-01-03
CN110997710A (zh) 2020-04-10
US20200283538A1 (en) 2020-09-10
EP3649149A1 (en) 2020-05-13
CA3068365A1 (en) 2019-01-10
GB201710620D0 (en) 2017-08-16
WO2019007869A1 (en) 2019-01-10
GB201810814D0 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
US11427643B2 (en) Targeted protein degradation
CN110392692B (zh) 抗pd-1抗体与突变体il-2或与il-15的免疫缀合物
ES2962588T3 (es) Proteínas de fusión de PD-1 y 4-1BB
CN114616244A (zh) 特异性结合mage-a的抗原结合蛋白
CA3054064A1 (en) Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
CN110913954A (zh) 免疫疗法的组合物和方法
CN113166226A (zh) 表达显性负性fas的免疫应答细胞及其用途
WO2017219937A1 (zh) 一种高效稳定表达抑制性抗体的car-t细胞及其用途
WO2017219936A1 (zh) 一种高效稳定表达激活型抗体的car-t细胞及其用途
US20220323494A1 (en) Novel Control Switch
EP2964675A1 (en) Engager cells for immunotherapy
US20250197472A1 (en) Programmable immunocyte receptor complex system
CN119053618A (zh) 嵌合ilt受体组合物和方法
CN115397867A (zh) Epcam抗体与car-t细胞
JP2023508608A (ja) 強化されたｔ細胞受容体ｓｔａｒ及びその用途
Farhat-Younis et al. Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity
CN118620056A (zh) Il-2变体及其用途
CN115279389A (zh) 新型显性负性Fas多肽、包含其的细胞及其用途
WO2022098797A1 (en) Therapeutic targeting of mesothelin in acute myeloid leukemia with chimeric antigen receptor t cell therapy
WO2024033544A1 (en) Deglycosylation of native glycoproteins expressed on a tumor cell surface
WO2024148369A1 (en) Targeted il-12 affinity variants
EA053037B1 (ru) Клетка, содержащая химерные рецепторы, нацеленные на adgre2 и/или clec12a, способ ее получения и ее применение, фармацевтическая композиция
BR112018069075B1 (pt) Métodos e composições para transduzir linfócitos e expansão regulada dos mesmos
HK40026640A (en) Compositions and methods for immunotherapy
HK1247625A1 (en) Masking chimeric antigen receptor t cells for tumor-specific activation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231013

R150 Certificate of patent or registration of utility model

Ref document number: 7369039

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150